指南与共识白血病MDS 与骨髓增殖性肿瘤

世界卫生组织与国际共识分类对嗜酸性粒细胞疾病的分类:2024年诊断、风险分层与管理更新

World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
指南 / 共识 · Am J Hematol · 2024-03-29

该指南基于2022年世界卫生组织与国际共识分类,综述嗜酸性粒细胞疾病的诊断、风险分层与治疗。嗜酸性粒细胞增多症定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L,需排除继发原因后结合形态学、遗传学、分子及流式检测明确克隆性。治疗以减轻嗜酸性粒细胞介导的器官损害为目标,包括观察等待、伊马替尼、培米替尼、糖皮质激素、羟基脲、干扰素α、美泊利单抗及造血干细胞移植等。

要点

  • 嗜酸性粒细胞增多症定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L,可伴组织损伤。
  • 诊断需排除继发原因,结合形态学、细胞遗传学、FISH、分子检测和流式免疫分型。
  • PDGFRA或PDGFRB重排的识别至关重要,因这类疾病对伊马替尼高度敏感。

核心结论

  • 嗜酸性粒细胞疾病涵盖非血液学和血液学疾病,诊断需排除继发原因并识别克隆性证据。
  • 治疗目标是减轻嗜酸性粒细胞介导的器官损害,根据亚型选择观察等待、靶向治疗、糖皮质激素、羟基脲、干扰素α、美泊利单抗或移植等。

研究设计与样本

  • 该文献为世界卫生组织与国际共识分类关于嗜酸性粒细胞疾病的2024年诊断、风险分层和管理更新。

主要发现

  • 嗜酸性粒细胞增多症一般定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • 2022年世界卫生组织与国际共识分类支持半分子分类方案,包括伴有酪氨酸激酶基因融合的髓系/淋系肿瘤和慢性嗜酸性粒细胞白血病。
  • 淋巴细胞变异型嗜酸性粒细胞增多症是异常T细胞克隆驱动的反应性嗜酸性粒细胞增多。
  • 特发性嗜酸性粒细胞增多综合征是排除性诊断。
  • 对于较轻的嗜酸性粒细胞增多(如小于1.5×10^9/L)无器官受累症状或体征者,可采取观察等待和密切随访。

关键数值与推荐

  • 嗜酸性粒细胞增多症一般定义为外周血嗜酸性粒细胞计数大于1.5×10^9/L。
  • 对于较轻的嗜酸性粒细胞增多(如小于1.5×10^9/L)无器官受累症状或体征者,可采取观察等待和密切随访。
  • PDGFRA或PDGFRB重排的识别至关重要,因这类疾病对伊马替尼高度敏感。
  • 培米替尼近期获批用于复发或难治性FGFR1重排肿瘤患者。
  • 糖皮质激素是淋巴细胞变异型嗜酸性粒细胞增多症和嗜酸性粒细胞增多综合征的一线治疗。

临床怎么用

  • 对于较轻的嗜酸性粒细胞增多(如小于1.5×10^9/L)无器官受累症状或体征者,可采取观察等待和密切随访。
  • 识别PDGFRA或PDGFRB重排至关重要,因这类疾病对伊马替尼高度敏感。
  • 糖皮质激素是淋巴细胞变异型嗜酸性粒细胞增多症和嗜酸性粒细胞增多综合征的一线治疗。
  • 羟基脲和干扰素α已显示作为嗜酸性粒细胞增多综合征的初始治疗和激素难治性病例的疗效。
  • 美泊利单抗是一种白细胞介素-5拮抗剂单克隆抗体,已获美国食品药品监督管理局批准用于特发性嗜酸性粒细胞增多综合征患者。

局限性

  • 细胞毒性化疗药物和造血干细胞移植已用于侵袭性嗜酸性粒细胞增多综合征和慢性嗜酸性粒细胞白血病,但报告结局的患者数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary or clonal) disorders with the potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109/L, and may be associated with tissue damage. After the exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests. They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ hybridization, molecular testing and flow immunophenotyping to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. RISK STRATIFICATION: Disease prognosis relies on identifying the subtype of eosinophilia. After evaluation of secondary causes of eosinophilia, the 2022 World Health Organization and International Consensus Classification endorse a semi-molecular classification scheme of disease subtypes. This includes the major category "myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions" (MLN-eo-TK), and the MPN subtype, "chronic eosinophilic leukemia" (CEL). Lymphocyte-variant HE is an aberrant T-cell clone-driven reactive eosinophila, and idiopathic hypereosinophilic syndrome (HES) is a diagnosis of exclusion. RISK-ADAPTED THERAPY: The goal of therapy is to mitigate eosinophil-mediated organ damage. For patients with milder forms of eosinophilia (e.g., <1.5 × 109/L) without symptoms or signs of organ involvement, a watch and wait approach with close follow-up may be undertaken. Identification of rearranged PDGFRA or PDGFRB is critical because of the exquisite responsiveness of these diseases to imatinib. Pemigatinib was recently approved for patients with relapsed or refractory FGFR1-rearranged neoplasms. Corticosteroids are first-line therapy for patients with lymphocyte-variant HE and HES. Hydroxyurea and interferon-α have demonstrated efficacy as initial treatment and in steroid-refractory cases of HES. Mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, is approved by the U.S Food and Drug Administration for patients with idiopathic HES. Cytotoxic chemotherapy agents, and hematopoietic stem cell transplantation have been used for aggressive forms of HES and CEL, with outcomes reported for limited numbers of patients. Targeted therapies such as the IL-5 receptor antibody benralizumab, IL-5 monoclonal antibody depemokimab, and various tyrosine kinase inhibitors for MLN-eo-TK, are under active investigation.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Shomali W, Gotlib J. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024. PMID: 38551368. doi:10.1002/ajh.27287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。